AMG 900

Drug Profile

AMG 900

Alternative Names: AMG-900

Latest Information Update: 26 Apr 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Amgen
  • Class Amines; Antineoplastics; Phthalazines; Pyrimidines; Small molecules
  • Mechanism of Action Aurora kinase A inhibitors; Aurora kinase B inhibitors; Aurora kinase C inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Haematological malignancies; Solid tumours

Most Recent Events

  • 26 Apr 2016 Results from a preclinical study presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 08 Apr 2016 Phase-I development is ongoing in USA and Australia
  • 01 Jan 2015 Amgen completes a phase I trial in Haematological malignancies (Second-line therapy or greater) in USA (NCT01380756)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top